These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19690235)

  • 21. Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Kourea K; Andreadou I; Ikonomidis I; Markantonis S; Ioannidis K; Paraskevaidis I; Iliodromitis E; Filippatos G; Kremastinos DT
    Am J Cardiol; 2009 Apr; 103(8):1134-8. PubMed ID: 19361602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients.
    Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M; Uchida K
    Adv Perit Dial; 2011; 27():60-4. PubMed ID: 22073831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicology and carcinogenesis studies of N,N-dimethyl-p-toluidine (CAS No. 99-97-8) in F344/N rats and B6C3F1/N mice (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2012 Sep; (579):1-211. PubMed ID: 23027199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury.
    Salahudeen AK; Haider N; Jenkins J; Joshi M; Patel H; Huang H; Yang M; Zhe H
    Am J Physiol Renal Physiol; 2008 Jun; 294(6):F1354-65. PubMed ID: 18385271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
    Ray-Coquard I; Laplaige P; Vey N; Asselain B; Urbieta M
    Curr Med Res Opin; 2010 Nov; 26(11):2653-60. PubMed ID: 20932223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
    Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
    Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
    Ludwig H; Crawford J; Osterborg A; Vansteenkiste J; Henry DH; Fleishman A; Bridges K; Glaspy JA
    J Clin Oncol; 2009 Jun; 27(17):2838-47. PubMed ID: 19380447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology of darbepoetin alfa.
    Macdougall IC; Padhi D; Jang G
    Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv2-iv9. PubMed ID: 17526547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain.
    Kumral A; Baskin H; Yesilirmak DC; Ergur BU; Aykan S; Genc S; Genc K; Yilmaz O; Tugyan K; Giray O; Duman N; Ozkan H
    Neonatology; 2007; 92(4):269-78. PubMed ID: 17627093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia.
    Lasocki S; Millot S; Andrieu V; Lettéron P; Pilard N; Muzeau F; Thibaudeau O; Montravers P; Beaumont C
    Crit Care Med; 2008 Aug; 36(8):2388-94. PubMed ID: 18664788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.